Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a pill beat sleepiness? new study puts alpha brain to the test

NCT ID NCT07495592

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study looks at whether a supplement called Alpha Brain can help healthy adults think more clearly, stay alert, and feel better when they haven't had enough sleep. About 34 people will take the supplement or a placebo in random order, with no one knowing which they got. The goal is to see if it improves reaction time and reduces fatigue during a short period of sleep deprivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

32 people

The number who actually took part.

Started

May 2026

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 59 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy males and females aged 20-59 * Free of chronic diseases. * Able to read and write in English * Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period * Willingness to meet all study requirements and restrictions. Including willing to arrive in lab in a sleep deprived state (\< or =5 hours), willing to avoid alcohol consumption 72 hours prior to testing days, and willing to avoid caffeine within 12 hours prior to testing days. Exclusion Criteria: * Habitual high caffeine consumers (\> 400 mg/day) assessed through caffeine assessment tool (Caffeine Consumption Questionnaire, CCQ) * Unwilling to wear sleep monitor at night * Known diagnosis of any cognitive impairment, cardiovascular, metabolic, endocrine, or renal disease * Has fever, or cold like symptoms * History of anxiety disorders * History of sleep disorders (i.e., insomnia), and habitually short sleepers (\<5 hours of sleep nightly) * History or current malignancy * Previous gastrointestinal surgery within the past 12 months * No alcohol consumption 72 hours prior to the start of the study/consumption of the study product and during the testing days * No caffeine consumption within 12 hours prior to the start of the study and during the testing days * Sleep medicines, melatonin, or marijuana within 1 week of the start of the study * Regular smoker * Regular drinker (\>14 drinks per week) * Current use (within the past 4 weeks) of dietary supplements or prescription medicines that may enhance cognitive performance (including, but not limited to L-Theanine, Cat's claw bark extract, Alpha GPC, Toothed clubmoss extract (Huperzine A), Bacopa, Phosphatidylserine, Paraxanthine, Pterostilbene, and Sceletium tortuosum). * Current use of prescription medications that may influence cognition (hormone therapies, peptides, etc.) * Travel involving time zone change, shift work, or other life events that alter sleep schedule \>3 hours from the norm one week before the start of the study * Any subject with a condition deemed by the investigator or sponsor to potentially interfere with study participation * Women who have been pregnant within the past 6-months, are breastfeeding, lactating, or presently planning to become pregnant during the duration of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder Fatigue Sleep Deprivation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Applied Science Performance Institute

    Tampa, Florida, 33634, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.